文拉法辛治疗持续性躯体形式疼痛障碍35例  

Venlafaxine in the Treatment of 35 Cases of Persistent Somatoform Pain Disorder

作　　者：徐景环[1] 李松芝[2] 

机构地区：[1]山东省滨州市人民医院药剂科 [2]山东省滨州市人民医院精神科,256610

出　　处：《医药导报》2004年第6期392-393,共2页Herald of Medicine

摘　　要：目的:观察文拉法辛治疗持续性躯体形式疼痛障碍的疗效。方法:将持续性躯体形式疼痛障碍初诊患者70例随机分为治疗组和对照组各35例,两组分别给予文拉法辛和阿米替林,均以25 mg,po,bid,根据病情渐增至50mg,po,tid。分别在治疗后第4天和第1,2,4周评定疗效。结果:治疗组和对照组完全缓解分别为9,8例,明显缓解分别为13,10例,轻度缓解分别为8,10例,无效分别为5,7例;有效率分别为85.71％,80.00％;两组间差异无显著性(P>0.05)。但治疗组口干、便秘、视物模糊、心动过速、嗜睡等不良反应明显比对照组少(P<0.01)。结论:文拉法辛对持续性躯体形式疼痛障碍疗效好,不良反应小,安全性高。Objective: To survey the therapeutic effectiveness of venlafaxine in the treatment of persistent somatoform pain disorder. Methods: 70 first visit outpatients meeting the CCMD-3 criteria were randomly divided into the treatment (venlafaxine) group (n=35) and control (amitryptiline) group (n=35). Patients of the treatment group and control group were given each initially 25 mg of vanlafaxine and amitryptiline PO b. i. d., respectively. According to the patients' condition, the doses of both drugs were gradually increased to 50 mg PO t. i. d.. The therapeutic effectiveness was appraised 4 days after the beginning of the treatment as well as in the 1st, 2nd and 4th weeks of the treatment. Results: Complete remission of symptoms was shown in 9 and 8 patients, definite remission in 13 and 10 patients, slight remission in 8 and 10 patients and no remission in 5 and 7 patients of the treatment group and control group, respectively. The effective rates of the treatment group and control group were 85.71% and 80.00%, respectively, the difference being insignificant (P>0.05). However, the incidence of adverse reactions including xerostomia, constipation, blurred vision, tachycardia and somnolence was apparently lower in patients of the treatment group than that of the control group(P<0.01). Conclusion: Venlafaxime was shown to be fairly effective and safe in the treatment of persistent somatoform pain disorder, with a low incidence of adverse reactions.

关 键 词：文拉法辛 阿米替林 躯体形式疼痛障碍 持续性 

分 类 号：R971.43[医药卫生—药品] R441.1[医药卫生—药学]